FDA grants Priority Review to Johnson & Johnson’s RYBREVANT FASPRO™ sBLA for subcutaneous treatment in advanced head and neck cancer

Johnson & Johnson said the U.S. Food and Drug Administration has granted Priority Review to its supplemental biologics license application (sBLA) for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a combination therapy intended for subcutaneous use in advanced head and neck cancer.

Priority Review is an FDA program that aims to shorten the agency’s review timeline for certain applications deemed to address serious conditions and fill important medical needs. In announcing the Priority Review decision, Johnson & Johnson framed the submission as a step toward expanding the therapy’s potential role in head and neck cancer with a delivery approach designed for patients outside of a traditional intravenous setting.

RYBREVANT FASPRO consists of amivantamab, an antibody that targets the epidermal growth factor receptor (EGFR), and the MET receptor. The “hyaluronidase-lpuj” component helps the medication spread and be absorbed when administered under the skin, enabling a subcutaneous route rather than an infusion.

In the company’s statement, the sBLA tied to RYBREVANT FASPRO was described as a potential first-in-class subcutaneous treatment aimed at advanced head and neck cancer that is driven by EGFR- and MET-targeting biology. The company did not, in the information provided, specify the exact patient subgroup, prior lines of therapy, or additional endpoints that supported the supplemental application.

Johnson & Johnson did not disclose in the reported announcement what the FDA’s Priority Review decision means for the expected review clock, including any target action date, nor did it provide details on the agency’s preliminary questions, supplementary data requests, or any safety findings at this stage.

The FDA Priority Review comes as regulators and drug developers continue to examine ways to improve both clinical outcomes and administration convenience in oncology, especially where repeated dosing can affect patient quality of life and treatment logistics. A shift toward subcutaneous administration, if ultimately approved and supported by evidence, can reduce time spent in infusion centers, although it typically requires careful demonstration of comparable pharmacokinetics, efficacy, and safety to intravenous approaches.

For now, the company’s disclosure is limited to the Priority Review status of the supplemental filing. Additional specifics that investors and clinicians will likely want, such as the study population, comparative context, and how the subcutaneous formulation’s results line up against existing standards of care, were not included in the excerpted report.

The next key development is the outcome of the FDA’s Priority Review process for the sBLA. For patients, clinicians, and the market, attention will likely center on whether the FDA accepts the application for approval and what, if any, restrictions or prescribing conditions accompany a potential authorization for RYBREVANT FASPRO in advanced head and neck cancer.